The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Subsequent anticancer medication following first-line lenvatinib: A posthoc responder analysis from the phase 3 REFLECT study in unresectable hepatocellular carcinoma.
 
Angel Alsina
Honoraria - Vital Therapies
Consulting or Advisory Role - Vital Therapies
Speakers' Bureau - Eisai
 
Masatoshi Kudo
Honoraria - Abbvie; Bayer; Bristol-Myers Squibb Japan; EA Pharma; Eisai; Gilead Sciences; Merck Serono; Merck Serono; MSD; Novartis; Pfizer; Taiho Pharmaceutical
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Eisai; MSD
Research Funding - Abbvie (Inst); Astellas Pharma (Inst); Bristol-Myers Squibb Japan (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Otsuka (Inst); Taiho Pharmaceutical (Inst)
 
Arndt Vogel
Honoraria - Amgen; Bayer; Bristol-Myers Squibb; Delcath Systems; Lilly; MSD; Novartis; Roche; Sanofi
Consulting or Advisory Role - Amgen; Baxalta; Bayer; Delcath Systems; Lilly; Novartis; Roche
Research Funding - Novartis
Travel, Accommodations, Expenses - Bayer; Ipsen; Roche
 
Ann-Lii Cheng
Honoraria - Bayer; Bristol-Myers Squibb; Merck; MSD; Novartis; Ono Pharmaceutical
 
Won Young Tak
Consulting or Advisory Role - Abbvie; Bayer; Bukwang Pharmaceutical; Eisai; Gilead Sciences; Ono Pharmaceutical; Samil Pharmaceutical; Yuhan
 
Baek-Yeol Ryoo
No Relationships to Disclose
 
T.R. Jeffry Evans
Honoraria - Bristol-Myers Squibb; Eisai
Consulting or Advisory Role - Bristol-Myers Squibb; Celgene; Eisai; Karus Therapeutics
Speakers' Bureau - Bristol-Myers Squibb; Celgene; Eisai
Research Funding - AstraZeneca (Inst); Basilea (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Daiichi Sankyo (Inst); Eisai (Inst); GlaxoSmithKline (Inst); Immunocore (Inst); Lilly (Inst); Merck (Inst); Nutide (Inst); Ono Pharmaceutical (Inst); Roche (Inst); Sierra Oncology (Inst); Verastem (Inst); Vertex (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb
 
Carlos López-López
Honoraria - Bayer; Eisai; Ipsen
Consulting or Advisory Role - AstraZeneca; Bayer; Bristol-Myers Squibb; Eisai; Ipsen
Speakers' Bureau - Bayer; Bristol-Myers Squibb; Eisai; Ipsen
Research Funding - AstraZeneca; Bristol-Myers Squibb; Eisai; Ipsen; MSD; Roche
Travel, Accommodations, Expenses - Bayer; Eisai; Ipsen; Roche
 
Bruno Daniele
Honoraria - Bayer; Bristol-Myers Squibb
Consulting or Advisory Role - Bayer; Eisai; Ipsen; Lilly; MSD
Travel, Accommodations, Expenses - Amgen; Bayer; Bristol-Myers Squibb; Celgene; Sanofi
 
Soamnauth Misir
Employment - Eisai
 
Min Ren
Employment - Eisai
 
Namiki Izumi
Speakers' Bureau - Bayer; Eisai
 
Shukui Qin
No Relationships to Disclose
 
Richard S. Finn
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Eisai; Genentech/Roche; Lilly; Merck; Novartis; Pfizer
Research Funding - Bayer (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst)